In the present study, we conducted a prospective observational study aimed at evaluating the stability of both humoral and cellular immune responses specific to the Wuhan and Omicron variant spike proteins in a real-world cohort of MM patients, between 16 and 26 weeks following the third SARS-CoV-2 vaccine dose. The gene discussed is CHMP5; the disease is Miyoshi myopathy.